DK1105105T3 - Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler - Google Patents

Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler

Info

Publication number
DK1105105T3
DK1105105T3 DK99941537T DK99941537T DK1105105T3 DK 1105105 T3 DK1105105 T3 DK 1105105T3 DK 99941537 T DK99941537 T DK 99941537T DK 99941537 T DK99941537 T DK 99941537T DK 1105105 T3 DK1105105 T3 DK 1105105T3
Authority
DK
Denmark
Prior art keywords
ylmethylsulfinyl
benzimidazoles
pyridin
oral administration
administration form
Prior art date
Application number
DK99941537T
Other languages
Danish (da)
English (en)
Inventor
Rango Dietrich
Hartmut Ney
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1105105(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of DK1105105T3 publication Critical patent/DK1105105T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK99941537T 1998-08-12 1999-08-07 Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler DK1105105T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98115141 1998-08-12

Publications (1)

Publication Number Publication Date
DK1105105T3 true DK1105105T3 (da) 2006-07-17

Family

ID=8232445

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99941537T DK1105105T3 (da) 1998-08-12 1999-08-07 Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler

Country Status (12)

Country Link
US (3) US7041313B1 (de)
EP (1) EP1105105B1 (de)
JP (1) JP4988088B2 (de)
AT (1) ATE321538T1 (de)
AU (2) AU772726B2 (de)
CA (2) CA2507743C (de)
DE (1) DE69930648T2 (de)
DK (1) DK1105105T3 (de)
ES (1) ES2262335T3 (de)
PT (1) PT1105105E (de)
SI (1) SI1105105T1 (de)
WO (1) WO2000009092A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
JP3977250B2 (ja) * 2000-10-18 2007-09-19 タイコ ヘルスケア グループ リミテッド パートナーシップ 吻合器具
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US7241302B2 (en) 2001-10-18 2007-07-10 Tyco Healthcare Group Lp Anastomosis instrument and method for performing same
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US11096948B2 (en) 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JP2602518B2 (ja) 1988-01-27 1997-04-23 エーザイ株式会社 被覆された胃酸分泌抑制剤含有組成物
DE3822095A1 (de) 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
ES2057338T3 (es) 1989-11-29 1994-10-16 Toa Eiyo Ltd Derivados de cicloheptenopiridina, procedimiento para su preparacion y agentes antiulcerosos que los contienen.
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
KR930006431B1 (ko) 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
JPH0710758A (ja) * 1993-06-22 1995-01-13 Nippon Iyakuhin Kogyo Kk 持続性セファクロル製剤
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
PL186605B1 (pl) 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts

Also Published As

Publication number Publication date
EP1105105A1 (de) 2001-06-13
JP2002522472A (ja) 2002-07-23
US20060263426A1 (en) 2006-11-23
EP1105105B1 (de) 2006-03-29
ES2262335T3 (es) 2006-11-16
WO2000009092A1 (en) 2000-02-24
DE69930648T2 (de) 2006-12-21
CA2507743C (en) 2008-03-18
PT1105105E (pt) 2006-07-31
AU5511499A (en) 2000-03-06
DE69930648D1 (de) 2006-05-18
CA2340054C (en) 2005-10-18
US20080226712A1 (en) 2008-09-18
US7041313B1 (en) 2006-05-09
AU772726B2 (en) 2004-05-06
US7402321B2 (en) 2008-07-22
US8465767B2 (en) 2013-06-18
AU2004202162A1 (en) 2004-06-17
AU2004202162B2 (en) 2007-03-08
JP4988088B2 (ja) 2012-08-01
CA2340054A1 (en) 2000-02-24
SI1105105T1 (sl) 2006-08-31
CA2507743A1 (en) 2000-02-24
ATE321538T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
DK1105105T3 (da) Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
PT1109812E (pt) Pirrolobenzodiazepinas
ATE303809T1 (de) Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
EA199900373A2 (ru) Фармацевтические композиции
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
DK1385515T3 (da) Spiropyrazole forbindelser
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
DK0469440T3 (da) Faste orale applikationsformer, der som aktivt stof indeholder ifosamid
EP0816366A4 (de) Imidazothiazolverbindungen
ES2170168T3 (es) Composiciones recubiertas entericamente de derivados de 1,5-benzodiacepina con actividad antagonista o agonista de cck.
SE9701438D0 (sv) A new process
DK1052995T3 (da) Farmaceutisk præparat til nasal indgivelse af thiocolchicosid
ATE288738T1 (de) Orale zusammensetzung
SE9901340D0 (sv) Novel process
MY137801A (en) Tablet for oral administration comprising 2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl-5-(1h-pyrrol-1-yl)-1h-benzimidazole
ECSP972052A (es) Quinoxalinadionas
SE9901338D0 (sv) Novel process